One year of qualification
Audited Supplier
In This Store
![(R)-3-Methyl-5-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1,2,4-thiadiazole Hy](https://eimg.pharmasources.com/image/20250224/JZn7IupRBYKVyk7bXuiudYYKqamIU8j7cr8ULJjk.gif!200)
(R)-3-Methyl-5-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1,2,4-thiadiazole Hy
(R)-tert-butyl 4-(4-(6-aMino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)
3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(MethylaMino)pyriMidine-2,4(1H,3H)-dione Cas No.871700-22-
Shijiazhuang Dingmin Pharmaceutical Sciences Co., Limited is a professional company focusing on the R&D, production, marketing and technical service of APIs and pharmaceutical intermediates. We have a R&D center and two plants in Shijiazhuang, Hebei Province. Our Products include active pharmaceutical ingredients (API), pharmaceutical and agrochemical intermediates and chiral compounds. We have won the trust of a wide range of customers/partners in the industry. Our major products are antineoplastic, cardiovascular and antibiotics and their intermediates.
In order to maintain continuous innovation and R & D capability, we maintain long-term and close cooperation with many research institutions and universities, Our co-production plants are located in Anhui, Jiangsu, Zhejiang and Inner Mongolia. The products have been sold to Europe, America, Southeast Asia and other countries and regions
Having upholding the " integrity, profession , innovation, win-win" as business philosophy, we believe that we are able to be stronger and stronger because of the excellent quality, favorable price and full-hearted service. We would like to sincerely welcome friends from all sectors to co-create a brilliant tomorrow together.
Year of Establishment: 2014
Total Assets(USD): 500,000 to 99,999,999
Total Number of Staff: 10-50
Main Competitive Advantages: Experienced R&D Staff,Production Capacity,Large Product Line,Buyers' Specifications Accepted,Small Orders Accepted,Quality Service
Other Competitive Advantages:
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094
Follow Us：
Pharma Sources Insight July 2025
![5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide Cas No.1350653-27-8](https://eimg.pharmasources.com/image/20250217/rObZtiaVmet4erEO86PA0I6G15dCjidBPEp2wZen.gif!200)
![(7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine Cas 1268364-45-9](https://eimg.pharmasources.com/image/20250205/OCNv9l8X2RSKT1arXkJnQ1EegbLhTjgJvjVpTArg.gif!200)
![N-[6-Chloro-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,a,a-trimethy Cas 825643-73-0](https://eimg.pharmasources.com/image/20250205/ZcCgvZMWBnfTFRZv4yQM01cKY4RU3dTmhBYw6M2R.gif!200)
![(7S,9aS)-7-((benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine dioxalate salt Cas 1268364-46-0](https://eimg.pharmasources.com/image/20250205/bWG6KPhyi1h4sXbqsb2469lCfm0MHLTSmD0bBY9A.gif!200)
![5,5'-octylidenebis[6-amino-1,3-dimethyl]-2,4-(1H,3H)-Pyrimidinedione] Cas 253195-26-5](https://eimg.pharmasources.com/image/20250205/08QFGIcgw1rGvAMF9P2Sh5gr3Tt0UEhXHVKo4yOw.gif!200)
